[go: up one dir, main page]

MX2014007170A - Moleculas de anticuerpo de union a trombina y sus usos. - Google Patents

Moleculas de anticuerpo de union a trombina y sus usos.

Info

Publication number
MX2014007170A
MX2014007170A MX2014007170A MX2014007170A MX2014007170A MX 2014007170 A MX2014007170 A MX 2014007170A MX 2014007170 A MX2014007170 A MX 2014007170A MX 2014007170 A MX2014007170 A MX 2014007170A MX 2014007170 A MX2014007170 A MX 2014007170A
Authority
MX
Mexico
Prior art keywords
thrombin
antibody molecules
binding antibody
exosite
recognise
Prior art date
Application number
MX2014007170A
Other languages
English (en)
Other versions
MX353281B (es
Inventor
James Andrew Huntington
Trevor Baglin
Jonathan Langdown
Original Assignee
Cambridge Entpr Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cambridge Entpr Ltd filed Critical Cambridge Entpr Ltd
Publication of MX2014007170A publication Critical patent/MX2014007170A/es
Publication of MX353281B publication Critical patent/MX353281B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Esta invención se refiere a anticuerpos aislados que reconocen el epítopo de exositio 1 de trombina y selectivamente inhiben trombina sin promover sangrado. Estas moléculas de anticuerpo pueden ser útiles en el tratamiento y prevención de trombosis, embolismo y otras condiciones mediadas por trombina.
MX2014007170A 2011-12-14 2012-12-14 Moleculas de anticuerpo de union a trombina y sus usos. MX353281B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1121513.4A GB201121513D0 (en) 2011-12-14 2011-12-14 Thrombin-binding antibody molecules and uses thereof
PCT/GB2012/053140 WO2013088164A1 (en) 2011-12-14 2012-12-14 Thrombin-binding antibody molecules and uses thereof

Publications (2)

Publication Number Publication Date
MX2014007170A true MX2014007170A (es) 2015-04-17
MX353281B MX353281B (es) 2018-01-08

Family

ID=45560465

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018000197A MX376876B (es) 2011-12-14 2012-12-14 Moleculas de anticuerpo de union a trombina y sus usos.
MX2014007170A MX353281B (es) 2011-12-14 2012-12-14 Moleculas de anticuerpo de union a trombina y sus usos.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2018000197A MX376876B (es) 2011-12-14 2012-12-14 Moleculas de anticuerpo de union a trombina y sus usos.

Country Status (34)

Country Link
US (5) US9518129B2 (es)
EP (2) EP3275903A1 (es)
JP (2) JP6216954B2 (es)
KR (1) KR102114506B1 (es)
CN (2) CN107936119B (es)
AU (2) AU2012351858B2 (es)
BR (1) BR112014014605A2 (es)
CA (1) CA2856656C (es)
CO (1) CO7101192A2 (es)
CY (1) CY1119599T1 (es)
DK (1) DK2791177T3 (es)
ES (1) ES2642718T3 (es)
GB (1) GB201121513D0 (es)
HK (1) HK1246326A1 (es)
HR (1) HRP20171775T1 (es)
HU (1) HUE034793T2 (es)
IL (1) IL232797B (es)
LT (1) LT2791177T (es)
ME (1) ME02901B (es)
MX (2) MX376876B (es)
MY (1) MY170980A (es)
NO (1) NO2791177T3 (es)
PE (2) PE20141706A1 (es)
PH (1) PH12014501169A1 (es)
PL (1) PL2791177T3 (es)
PT (1) PT2791177T (es)
RS (1) RS56510B1 (es)
RU (2) RU2642276C2 (es)
SG (1) SG11201402560WA (es)
SI (1) SI2791177T1 (es)
SM (1) SMT201700580T1 (es)
UA (1) UA116531C2 (es)
WO (1) WO2013088164A1 (es)
ZA (1) ZA201403836B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201121513D0 (en) 2011-12-14 2012-01-25 Cambridge Entpr Ltd Thrombin-binding antibody molecules and uses thereof
US9518128B2 (en) * 2011-12-14 2016-12-13 Janssen Pharmaceuticals, Inc. Thrombin-binding antibody molecules
GB201310949D0 (en) * 2013-06-19 2013-07-31 Cambridge Entpr Ltd Binding Motif
GB201310948D0 (en) * 2013-06-19 2013-07-31 Cambridge Entpr Ltd Screening methods
MX2018009264A (es) * 2016-02-05 2018-08-28 Jiangsu Hengrui Medicine Co Anticuerpo de trombina, fragmento de antigeno y sus usos farmaceuticos.
CN107043423B (zh) * 2016-02-05 2021-02-26 江苏恒瑞医药股份有限公司 凝血酶抗体、其抗原结合片段及医药用途
WO2018081534A1 (en) * 2016-10-28 2018-05-03 President And Fellows Of Harvard College Assay for exo-site binding molecules
WO2019030706A1 (en) 2017-08-10 2019-02-14 Janssen Pharmaceutica Nv ANTI-THROMBIN ANTIBODY MOLECULES AND METHODS OF USE IN ORTHOPEDIC SURGERY
WO2019035055A1 (en) 2017-08-16 2019-02-21 Janssen Pharmaceutica Nv ANTI-THROMBIN ANTIBODY MOLECULES AND METHODS OF USE WITH PLATELET ANTI-AGGREGATE AGENTS
WO2020003077A1 (en) * 2018-06-25 2020-01-02 Janssen Pharmaceutica Nv Anti-thrombin antibody molecules for use in patients at risk for gastrointestinal (gi) bleeding

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0417193B1 (en) * 1988-05-27 1993-08-04 Centocor, Inc. Freeze-dried formulation for antibody products
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5240913A (en) 1989-08-18 1993-08-31 Biogen, Inc. Inhibitors of thrombin
US5196404B1 (en) 1989-08-18 1996-09-10 Biogen Inc Inhibitors of thrombin
CA2082643A1 (en) 1990-05-10 1991-11-11 Jan H. Nuijens Inhibitors of factor xii activation and applications thereof
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5443827A (en) * 1993-05-03 1995-08-22 President And Fellows Of Harvard College Fibrin-targeted inhibitors of thrombin
CA2180140A1 (en) * 1993-12-27 1995-07-06 Jeffrey I. Weitz Methods and compositions for inhibiting thrombogenesis
GB9613718D0 (en) 1996-06-29 1996-08-28 Thrombosis Res Inst Thrombin inhibitors
US5985833A (en) 1996-09-17 1999-11-16 Wisconsin Alumni Research Foundation Thrombin inhibitor
WO2001000667A2 (en) 1999-06-29 2001-01-04 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-thrombin peptide from anopheles albimanus salivary gland
CA2378473A1 (en) * 1999-07-23 2001-02-01 The Regents Of The University Of California Modulation of platelet activation
CN100339132C (zh) * 2000-05-15 2007-09-26 史密丝克莱恩比彻姆公司 抗血栓剂
WO2002017711A2 (en) 2000-08-31 2002-03-07 Cor Therapeutics, Inc. Therapeutics and diagnostics based on a novel signal transduction system in platelets
CA2453202C (en) * 2001-07-06 2012-10-16 Oregon Health & Science University Peptides which modulate blood coagulation and methods of use thereof
TWI338009B (en) * 2001-10-29 2011-03-01 Genentech Inc Antibodies for inhibiting blood coagulation and methods of use thereof
MEP0208A (xx) 2005-08-26 2010-02-10 Archemix Corp Aptameri koji vezuje trombin sa visokim afininitetom
JP2009530312A (ja) 2006-03-15 2009-08-27 エモリー ユニヴァーシティ トロンビン阻害剤の抗凝固効果を阻害するためのトロンビン変異体の使用
GB0711779D0 (en) 2007-06-18 2007-07-25 Univ Singapore Thrombin inhibitor
PL2297207T3 (pl) 2008-06-19 2019-03-29 Prothix Bv Zastosowanie przeciwciał przeciw czynnikowi XI do zapobiegania lub leczenia tworzenia skrzepliny
US20110275701A1 (en) 2008-09-18 2011-11-10 Archemix Corp. Anti-thrombin aptamer formulations and methods for use
LT2734552T (lt) 2011-07-22 2025-01-10 Csl Behring Gmbh Inhibitoriniai monokloniniai antikūnai prieš xii/xiia faktorių ir jų panaudojimas
US9518128B2 (en) 2011-12-14 2016-12-13 Janssen Pharmaceuticals, Inc. Thrombin-binding antibody molecules
GB201121513D0 (en) * 2011-12-14 2012-01-25 Cambridge Entpr Ltd Thrombin-binding antibody molecules and uses thereof

Also Published As

Publication number Publication date
SI2791177T1 (en) 2018-03-30
LT2791177T (lt) 2017-11-27
UA116531C2 (uk) 2018-04-10
PT2791177T (pt) 2017-11-29
US20210371543A1 (en) 2021-12-02
CY1119599T1 (el) 2018-04-04
MY170980A (en) 2019-09-23
US10287363B2 (en) 2019-05-14
RU2017144629A3 (es) 2021-04-05
US9988463B2 (en) 2018-06-05
RU2642276C2 (ru) 2018-01-24
EP3275903A1 (en) 2018-01-31
US20190276558A1 (en) 2019-09-12
AU2017268655B2 (en) 2019-05-09
SMT201700580T1 (it) 2018-01-11
JP2015501830A (ja) 2015-01-19
PE20190171A1 (es) 2019-02-01
CA2856656C (en) 2021-01-19
RS56510B1 (sr) 2018-02-28
EP2791177B1 (en) 2017-09-06
US20170066842A1 (en) 2017-03-09
PH12014501169B1 (en) 2014-09-08
HK1202564A1 (en) 2015-10-02
IL232797B (en) 2018-07-31
CO7101192A2 (es) 2014-10-31
JP6216954B2 (ja) 2017-10-25
WO2013088164A1 (en) 2013-06-20
US9518129B2 (en) 2016-12-13
RU2017144629A (ru) 2019-02-18
ES2642718T3 (es) 2017-11-17
NO2791177T3 (es) 2018-02-03
PH12014501169A1 (en) 2014-09-08
AU2012351858B2 (en) 2017-10-05
RU2014124985A (ru) 2016-02-10
IL232797A0 (en) 2014-07-31
ME02901B (me) 2018-04-20
EP2791177A1 (en) 2014-10-22
AU2017268655A1 (en) 2017-12-21
KR102114506B1 (ko) 2020-05-22
SG11201402560WA (en) 2014-06-27
KR20140105556A (ko) 2014-09-01
PL2791177T3 (pl) 2018-03-30
JP2018039798A (ja) 2018-03-15
HRP20171775T1 (hr) 2017-12-29
HK1246326A1 (en) 2018-09-07
US20140370008A1 (en) 2014-12-18
HUE034793T2 (en) 2018-02-28
JP6705785B2 (ja) 2020-06-03
MX353281B (es) 2018-01-08
CN104053673B (zh) 2018-01-12
AU2012351858A1 (en) 2014-06-12
MX376876B (es) 2025-03-07
CN104053673A (zh) 2014-09-17
CN107936119A (zh) 2018-04-20
CN107936119B (zh) 2021-06-15
GB201121513D0 (en) 2012-01-25
BR112014014605A2 (pt) 2017-06-13
ZA201403836B (en) 2015-12-23
NZ625386A (en) 2017-03-31
PE20141706A1 (es) 2014-11-13
US20180334511A1 (en) 2018-11-22
DK2791177T3 (en) 2017-12-18
CA2856656A1 (en) 2013-06-20

Similar Documents

Publication Publication Date Title
PH12014501169A1 (en) Thrombin-binding antibody molecules and uses thereof
PH12018502225A1 (en) Anti-il-33 antibodies, compositions, methods and uses thereof
TN2012000366A1 (en) Anticoagulant antidotes
MX2018000147A (es) Moleculas de anticuerpo que se unen al grupo de diferenciacion 45 (cd45).
MX2018000470A (es) Moleculas de anticuerpo que se unen al grupo de diferenciacion 22 (cd22).
MX2018010572A (es) Inmunoglobulinas heterodimericas.
MX2021013665A (es) Proteinas de union a calicreina en plasma y usos de las mismas para tratar el angioedema hereditario.
WO2017015622A3 (en) Gdf11 binding proteins and uses thereof
MX2016000719A (es) Composiciones y metodos que comprenden una variante de enzima lipolitica.
MX382540B (es) Proteinas de fusion para inhibir la angiogenesis
PH12017500864A1 (en) Anti-notch1 antibodies
PH12014501410A1 (en) Compositions and methods for antibodies targeting factor p
MX2018000590A (es) Moleculas de anticuerpo que se unen a agrupacion de diferenciacion 79 (cd79).
EA201291065A1 (ru) Антитела против vla-4
WO2012050611A3 (en) Aptamers to glycoprotein vi
MX2012001306A (es) Inhibicion de matastasis de tumor.
WO2014159669A3 (en) Aptamers that bind to il-6 and their use in treating or diagnosing il-6 mediated conditions
TN2015000277A1 (en) Bmp-6 antibodies
TN2013000388A1 (en) Anticoagulant antidotes
WO2013067160A3 (en) Anti-bacterial polypeptides and pathogen specific synthetic antibodies
SG10201807066UA (en) Peptides and methods of use
EA201501176A1 (ru) Замещенные бензоксазолы
HK1199842A1 (en) Anti-siglec-15 antibodies and uses thereof
UA108562C2 (ru) Железоуглеродистый брикет

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: JANSSEN PHARMACEUTICALS, INC.*

FG Grant or registration